New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).

ESMO Open
Angelika M Starzer, Anna S Berghoff

Abstract

Cluster of differentiation 27 (CD27) is a member of the tumour necrosis factor receptor superfamily and plays a key role in T-cell activation by providing a costimulatory signal. Bound to its natural ligand CD70, CD27 signalling enhances T-cell proliferation and differentiation to effector and memory T cells and therefore has potential as an immune modulatory target in cancer treatment. The CD27 agonistic antibody varlilumab showed promising efficacy in haematological as well as solid cancers. Current studies investigate the combination of the CD27 agonistic antibody varlilumab in combination with the PD1 axis targeting immune checkpoint inhibitors like nivolumab or atezolizumab. Further, CD70 expression is used as a therapeutic target for ADCs, antibodies inducing ADCC, as well as the immunological target for chimeric antigen receptor gene-modified T cells and specific dendritic cell vaccination. In line with this, targeting the CD27 axis was shown to be feasible and safe in early clinical trials with the most commonly occurring side effects being thrombocytopenia, fatigue and nausea. In this mini review, we aimed to elucidate the immunobiology of CD27 and its potential as a target in cancer immunotherapy.

References

Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·T KobataC Morimoto
Nov 25, 1998·Seminars in Immunology·S M LensR A van Lier
Aug 25, 1999·British Journal of Haematology·S M LensM H van Oers
Feb 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K TakedaK Okumura
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S MorimotoT Kobata
Apr 27, 2000·Immunology Today·K AgematsuA Komiyama
Feb 14, 2002·Trends in Biochemical Sciences·Jean-Luc BodmerJürg Tschopp
Dec 7, 2002·Nature Immunology·Kiki TesselaarRené A W van Lier
Dec 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kiki TesselaarRené A W van Lier
May 14, 2003·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Marleen KokMarie José Kersten
Sep 17, 2003·Nature Reviews. Immunology·Michael Croft
May 22, 2004·Cancer Gene Therapy·Carine CormaryAnne-Françoise Tilkin-Mariamé
Jun 9, 2004·The Journal of Experimental Medicine·Ramon ArensMarinus H J van Oers
May 12, 2005·Current Opinion in Immunology·Jannie BorstYanling Xiao
Feb 23, 2010·Biochemical and Biophysical Research Communications·Tamami Sakanishi, Hideo Yagita
May 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura A VitaleTibor Keler
May 26, 2012·Cancer Research·Christina ClausAdrian F Ochsenbein
Jan 22, 2013·Nature Reviews. Drug Discovery·Michael CroftCarl F Ware
Jul 12, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joeri J PenJoeri L Aerts
Aug 2, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S WilgenhofB Neyns
Sep 13, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Li-Zhen HeTibor Keler
Oct 27, 2015·Journal for Immunotherapy of Cancer·Venky RamakrishnaTibor Keler
Nov 19, 2015·Cancer Chemotherapy and Pharmacology·Taofeek Kunle OwonikokoLewis J Cohen
Feb 26, 2016·Expert Opinion on Therapeutic Targets·Harald Wajant
Dec 25, 2016·The Journal of Experimental Medicine·Hassan AbolhassaniQiang Pan-Hammarström
May 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisTimothy Bullock
Aug 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philippe AftimosAhmad Awada
Mar 9, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarah L BuchanAymen Al-Shamkhani

❮ Previous
Next ❯

Citations

Sep 29, 2020·Expert Opinion on Biological Therapy·Victor I Seledtsov, Alexei von Delwig
Sep 17, 2020·Oncoimmunology·Julie Le NaourErika Vacchelli
Aug 28, 2021·Cancers·Florentine E F TimmerTanja D de Gruijl
Sep 30, 2021·Scientific Reports·Ronald D SeidelRodolfo J Chaparro

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01460134
NCT01015911
NCT01677390
NCT02216890
NCT01497821
NCT01813539
NCT02759250
NCT00944905
NCT02335918
NCT02386111

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.